Products

Signal Tracker Data Platform Data Enrichment API Intelligence desk

Solutions

Inward Investment & Aftercare Deal Origination Executive Search Corporate Development Signal-Based Outbound Competitive Intelligence Funding Signals Competitor Monitoring For Sales Teams For Founders For Agencies For Investors

Explore

Companies Live Signals Markets Trends

Resources

Signal Checker Blog Integrations FAQ Contact
Login Book a demo
Ikonisys logo — Finding the cells that matter

Ikonisys

Finding the cells that matter

Founded 1999 France France 39 employees Post-IPO Equity Total: $50.06M Biotechnology, Health Care

General Information

Company Name Ikonisys
Founded Year 1999
Location France France
Employees 39
Industries Biotechnology, Health Care
Funding Stage Post-IPO Equity
Social

BounceWatch is an independent company data service, not affiliated with Ikonisys. To contact Ikonisys, visit ikonisys.com.

Is this your company?

Confirm with your work e-mail, get the Verified badge and keep this profile correct yourself. Search engines and AI assistants read it every day.

Get Verified

How does Ikonisys compare?

A PDF of Ikonisys and up to 10 competitors you pick: team, funding, traffic and every dated move of the last 90 days. Each company is re-checked on the day you order, so it is current.

See a sample report

This takes a few seconds: we look beyond our own index too.

Meeting Ikonisys soon?

A one-page PDF brief: what it does, key facts, the last 90 days of dated moves and questions worth asking. Re-checked on the day you order. See a sample

About Ikonisys

is a biotechnology startup based in France that is revolutionizing diagnostic medicine with its focus on early, accurate, and non-invasive disease detection. Its breakthrough fluorescence microscopy platform, Ikoniscope20®, is a robotic, high-throughput system that provides a walk-away automated solution for oncology tests. The platform not only captures high-quality cell images but also analyzes the cells of interest, offering an interpretation of the analysis for quick and accurate reporting of test results. Additionally, Ikonisys's platform is particularly suitable for circulating tumor cell-based testing, with rare cell detection and analysis capabilities that enable the examination of large complex samples for clinically relevant cells. The company, established in 1999, has received a recent €500.00K Post-IPO Equity investment as of 27 February 2025. While the specific investors for this round are not mentioned, Ikonisys's dedication to leveraging technology and science to advance disease detection and management positions it as an intriguing prospect for investors in the biotechnology and health care sectors. With its innovative approach and promising technology, Ikonisys represents a compelling opportunity for venture capital firms seeking to contribute to the advancement of diagnostic medicine.

Business keywords: Rare Cell Detection, Cancer Diagnostics, CTC, Liquid Biopsy, Medical Technology, Fluorescence Microscopy, Oncology Testing, Cell Analysis, Disease Detection, Diagnostic Medicine, Automated Microscopy, Robotic Technology, Clinical Research, Healthcare Innovation

Services & Products

Fluorescence In Situ Hybridization Technology
Automated Cancer Diagnostics
Rare Cell Detection
Microscope Slide Analysis
Genetic Testing Platform

Target Customers

Oncology Diagnostic Labs Pathologists Healthcare Professionals Medical Researchers Biomedical Engineers

Funding Rounds & Investors (9)

View All
Funding Stage Amount Investors Lead Investors Date
Post IPO Equity €500.00K -
27 Feb 2025
Post IPO Equity $200.00K -
19 Nov 2024
Post IPO Equity €150.00K -
04 Jun 2024
Post IPO Equity €500.00K 1
Cambria Equity Partners
15 Jun 2023
Venture Round $1.40M -
03 Aug 2012
Venture Round $3.81M -
04 Aug 2010
Series E $30.00M 5
Goldman Sachs New Science Ventures Lakeview Capital Management
Goldman Sachs, New Science Ventures +3
17 Oct 2007
Series D $10.00M 4
New Science Ventures Lakeview Capital Management WGI Group
New Science Ventures, Lakeview Capital Management +2
08 Mar 2006
Series C $3.50M -
11 Dec 2003

Ikonisys Alternatives & Competitors

View All Alternatives
Ikonisys vs
CytoTrack
CytoTrack

Discover the Future of Tumor Cell Detection with Unparalleled Precision and Speed

Grant
Biotechnology, Health Care
Compare Ikonisys vs CytoTrack
Ikonisys vs
Celldom, Inc.
Celldom, Inc. United States

Find and study cells that make diseases incurable

Seed
8 employees
Biotechnology, Health Care
Compare Ikonisys vs Celldom, Inc.
Ikonisys vs
RareCyte, Inc.
RareCyte, Inc. United States

A one-stop resource for Spatial Biology and Liquid Biopsy solutions.

Venture round
65 employees
Biotechnology, Health Care
Compare Ikonisys vs RareCyte, Inc.
Also compare with: Ikonisys vs ANGLE ANGLE Ikonisys vs Alamar Biosciences, Inc. Alamar Biosciences, Inc. View all alternatives

FAQ About Ikonisys

Finding the cells that matter
Ikonisys was founded in 1999.
Ikonisys is headquartered in France.
Ikonisys operates in Biotechnology and Health Care. Its work centres on Rare Cell Detection, Cancer Diagnostics, CTC and Liquid Biopsy. Its customers include Oncology Diagnostic Labs, Pathologists and Healthcare Professionals.
Ikonisys has approximately 39 employees.
Ikonisys has completed 9 funding rounds, raising a total of $50.06M. The latest funding stage is Post-IPO Equity.
Ikonisys offers: Fluorescence In Situ Hybridization Technology, Automated Cancer Diagnostics, Rare Cell Detection, Microscope Slide Analysis, Genetic Testing Platform.
Top alternatives and competitors to Ikonisys include CytoTrack, Celldom, Inc., RareCyte, Inc., GILUPI GmbH, CellMax Life. These companies operate in related industries and serve comparable markets. You can compare them side by side on Bounce Watch.
Ikonisys and CytoTrack are both companies in similar industries. Compare their funding, team size, growth signals, and market position on Bounce Watch to see which one fits your needs.

Source: BounceWatch company record for Ikonisys, https://bouncewatch.com/company/ikonisys, updated 7 June 2025. When citing, please name BounceWatch and link this page.

Analytics cookies (ours + Google). Cookie Policy

Book a demo 30 minutes